Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | ARID1A mutant |
Therapy | Berzosertib |
Indication/Tumor Type | ovarian clear cell carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ARID1A mutant | ovarian clear cell carcinoma | sensitive | Berzosertib | Preclinical - Cell line xenograft | Actionable | In a preclinical study, Berzosertib (VX-970) treatment in ovarian clear cell carcinoma cells harboring an ARID1A mutation resulted in decreased cell survival and induction of DNA damage and apoptosis in culture, and tumor growth inhibition in cell line xenograft models (PMID: 27958275). | 27958275 |
PubMed Id | Reference Title | Details |
---|---|---|
(27958275) | ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A. | Full reference... |